Court throws out Abbott AIDS-drug claims

Abbott Laboratories won a federal appeals court ruling dismissing claims that the company maintained a monopoly and overcharged for its HIV medicine Norvir, but still faces suits from competitors and drug-buyers over the price of the drug. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.